
Five years after the first reports linking gadolinium-based MRI contrast agents to nephrogenic system fibrosis (NSF), separate presentations of post-marketing data from manufacturers and an independent prospective study supported by agencies in France have validated the low-risk status of the contrast agent Dotarem (Gd-DOTA).

































